To examine whether integrating tumor genomic and immune microenvironment features had improved prediction of the efficacy for TNBC, we performed integrated analysis by combining both TMB and the ratio of CD8 T lymphocytes to M2 macrophages. The gene discussed is CD8A; the disease is neoplasm.